Atlas Trials

A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer

Clinical trial NCT05275777 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05275777
Sponsor
National University Hospital, Singapore
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
HER2-negative Breast CancerAdvanced Solid Tumor
Start date
2022-05-19
Primary completion
2027-12-01
Enrollment
66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.